The Life Sciences team advised BridgeBio Pharma, Inc. (NASDAQ: BBIO) and its affiliates Navire and QED on collaboration agreements with LianBio to expand BridgeBio’s global reach into China, the second-largest pharmaceutical market in the world. The partnership marks the first major expansion of BridgeBio’s pipeline into Asian markets.
BridgeBio is a clinical-stage biopharmaceutical company focused on genetic diseases and cancers with clear genetic drivers. The company’s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development. Shanghai-based LianBio is a new company founded by life sciences investment firm Perceptive Advisors to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries.
This strategic relationship will initially focus on two of BridgeBio’s targeted oncology drug candidates, FGFR inhibitor infigratinib, currently in Phase 3 development for FGFR-driven tumors and Phase 1-ready SHP2 inhibitor BBP-398, for tumors driven by RAS and receptor tyrosine kinase mutations. The agreement also provides LianBio with preferential future access in the territory to more than 20 drug development candidates currently owned or controlled by BridgeBio
Under the terms of the agreements, LianBio will receive commercial rights in China and selected Asian markets and participate in clinical development activities for infigratinib (housed in QED) and BBP-398 (housed in Navire). BridgeBio’s near-term economics includes a total of $26.5 million in upfront and milestone payments. BridgeBio will receive up to $505 million in future milestone payments, tiered royalty payments from single- to double-digits on net sales of both products in licensed territories.